尊龙凯时
About us
尊龙凯时:Our Values
尊龙凯时:Development Milestone
Products
尊龙凯时:Product List for API
尊龙凯时:Recommended API
Product list for Chemicals and Intermediates
Product list for Chemicals and Intermediates
News
尊龙凯时:Contract Manufacturing
API and Pharmaceutical Intermediates
尊龙凯时:OTC and Generics
尊龙凯时:Investor Relation
尊龙凯时:PERIODIC REPORT
尊龙凯时:INTERIM REPORT
尊龙凯时:INVESTORS SERVICE
尊龙凯时:Contact Us
About us
News
尊龙凯时:Investor Relation
Products
尊龙凯时:Contract Manufacturing
尊龙凯时:Contact Us
Investor Relation
Investor Relation
尊龙凯时:PERIODIC REPORT
尊龙凯时:INTERIM REPORT
尊龙凯时:INVESTORS SERVICE
Overseas Regulatory Announcement-Announcement on Esomeprazole Magnesium Having Obtained the Notification of Approval of Marketing Application for Chemical Substance Drugs
2024-09-02
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 August 2024
2024-09-02
Overseas Regulatory Announcement-Announcement on the Progress of Clinical Trial of OAB-14 Dry Suspension
2024-08-22
Interim Dividend For the Six Months Ended 30 June 2024
2024-08-22
Payment of 2024 Interim Dividend
2024-08-22
Announcement Notice of Board Meeting
2024-08-08
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 July 2024
2024-08-01
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 June 2024
2024-07-02
Articles of Association
2024-06-26
Overseas Regulatory Announcement-Announcement on Pregabalin Capsules Having Obtained the Drug Registration Certificate
2024-06-19
<
...
3
4
5
6
7
8
9
...
>